|
|
|||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||
Web Letter for Healthcare ProvidersThis is an archived document. The links and content are no longer being updated. XDR TB in TravelerDear Healthcare Professional, A person with recently diagnosed culture-confirmed, extensively drug-resistant pulmonary tuberculosis (XDR TB) traveled on the following two extended flights (more than 8 hours in duration) in May 2007:
XDR TB is defined as a subtype of multidrug resistant TB (MDR TB) (i.e., an isolate resistant to at least isoniazid and rifampin), with additional resistance to at least two of the most important second-line antibiotics (i.e., a fluoroquinolone and an injectable agent [amikacin, kanamycin, or capreomycin]). Since May 25, the patient has been hospitalized in airborne isolation or wearing an appropriate mask, and is now receiving medical therapy for XDR TB. He has remained relatively asymptomatic, and his sputum smear results were negative for acid fast bacilli (AFB), both before and after his travel; however, his sputum culture results are positive for XDR TB. This is the first investigation of a case of XDR TB during air travel. Due to the serious nature of this strain of TB disease, CDC is recommending that all U.S. residents and citizens on these two flights receive evaluation, testing, and follow-up for TB infection. We are requesting your assistance to perform TB evaluation and testing on any person identified as a contact on one of these flights. Access the XDR TB Contact Investigation Form (PDF - 83K) and enter the requested information. Please keep a copy of this completed form for your records, give a copy to the person tested, and also please contact your State or Local TB control office. For inquiries related to this investigation, please call your State or Local Health Department. For more information about XDR TB. We greatly appreciate your assistance on this important international XDR TB contact investigation.
Last Reviewed: 05/18/2008 |
|||||||||||||
|
If you would like to order any of the DTBE publications please visit the online order form. You will need Adobe Acrobat™ Reader v5.0 or higher to read pages that are in PDF format. Download the Adobe Acrobat™ Reader. If you have difficulty accessing any material on the DTBE Web site because of a disability, please contact us in writing or via telephone and we will work with you to make the information available. Division of Tuberculosis Elimination
Centers for Disease Control & Prevention |